Raising $500 million in additional funding to strengthen the core pipeline! Avidity (RNA.US) gets praised by Bank of America, with a target price as high as $65.

According to Zhixin Finance APP, Bank of America released a research report giving Avidity Biosciences Inc. (RNA.US) a "buy" rating and raising its target price from $56 to $65. Based on the company's latest closing price, the new target price implies a 45% upside potential for its stock price.